Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYO8
- Development stage
- Preclinical
- Lead developer
- Myocea
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**MYO8** is a preclinical small-molecule drug candidate from **Myocea** being developed for **spinal muscular atrophy**. In the company pipeline, MYO8 is the asset associated with **Network 4**, indicating an internal discovery-stage program aimed at modulating a proprietary SMA-relevant biological network linked to skeletal muscle and neuromuscular junction biology. Publicly available information does not define a more specific molecular target, binding mode, or pharmacologic effect beyond Network 4 modulation, and no clinical development, brand name, dosage form, or route of administration has been disclosed.
- Other names
- Myocea Network 4 small moleculeMyocea Network 4
02
Targets
NTN4 (Netrin-4)
Beyond the preview
Go deeper on MYO8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYO8.